Bristol Myers Squibb (CELG-RI) Cash from Investing Activities Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Cash from Investing Activities Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 93.92% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1.35% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -627.53% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -38.43% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -38.14% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -46.27% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -388.99% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -46.70% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 78.10% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -241.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -241.23% |
| Mar 31, 2026 | 73.75% |
| Dec 31, 2025 | -643.88% |
| Sep 30, 2025 | -677.17% |
| Jun 30, 2025 | 64.14% |
| Mar 31, 2025 | 97.46% |
| Dec 31, 2024 | 85.44% |
| Sep 30, 2024 | 46.59% |
| Jun 30, 2024 | -300.91% |
| Mar 31, 2024 | -9,241.90% |
| Dec 31, 2023 | -210.96% |
| Sep 30, 2023 | 80.30% |
| Jun 30, 2023 | -13.84% |
| Mar 31, 2023 | -321.05% |
| Dec 31, 2022 | 202.49% |
| Sep 30, 2022 | -113.22% |
| Jun 30, 2022 | -260.56% |
| Mar 31, 2022 | 166.43% |
| Dec 31, 2021 | 103.39% |
| Sep 30, 2021 | -358.22% |